These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7438902)

  • 1. [Madopar in the treatment of paralysis agitans. I. Therapeutic efficacy and side-effects in 56 cases (author's transl)].
    Liu DK
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1980; 13(3):147-50. PubMed ID: 7438902
    [No Abstract]   [Full Text] [Related]  

  • 2. [Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
    Liu DK
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1980 Apr; 13(4):223-6. PubMed ID: 6790255
    [No Abstract]   [Full Text] [Related]  

  • 3. Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD
    Adv Neurol; 1987; 45():493-6. PubMed ID: 3548262
    [No Abstract]   [Full Text] [Related]  

  • 4. Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
    Mondal BK; Mondal KN
    Pharmatherapeutica; 1986; 4(9):571-6. PubMed ID: 3094036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Levodopa and decarboxylase inhibitors in Parkinson's disease].
    Gilland O
    Lakartidningen; 1977 Jan; 74(1-2):37-40. PubMed ID: 318722
    [No Abstract]   [Full Text] [Related]  

  • 6. ["Immune type" haemolysis in course of L. dopa-benserazide therapeutic (author's transl)].
    Conte P; Moulinier J; Reiffers J; Julien J
    Nouv Presse Med; 1979 Jan; 8(1):46-7. PubMed ID: 554063
    [No Abstract]   [Full Text] [Related]  

  • 7. [The association of L-DOPA and Ro 4-4602 in the treatment of Parkinson's disease (author's transl)].
    Campanella G; Pennetta R
    Riv Patol Nerv Ment; 1974 Oct; 95(5):673-5. PubMed ID: 4470267
    [No Abstract]   [Full Text] [Related]  

  • 8. [Outcome of Parkinsonism after two years of levodopa plus R04-4602 (author's transl)].
    Faglioni P; Gasparini M; Spinnler H
    Riv Patol Nerv Ment; 1975; 96(4):270-86. PubMed ID: 785578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
    Pezzoli G; Tesei S; Ferrante C; Cossutta E; Zecchinelli A; Scarlato G
    Mov Disord; 1988; 3(1):37-45. PubMed ID: 3050471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
    Puca FM; Megna GF; Masi G; Specchio LM
    Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268
    [No Abstract]   [Full Text] [Related]  

  • 11. [Development of studies on the treatment of Parkinson syndromes using levodopa. I. Short- and medium-term (2 years) effects of the combination levodopa decarboxylase inhibitor].
    Rondot P; Ribadeau Dumas JL; Cardon P
    Therapie; 1975; 30(5):653-66. PubMed ID: 769245
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of CB 154 (2-bromo-alpha-ergocryptine) on paralysis agitans compared with Madopar in a double-blind, cross-over trial.
    Gerlach J
    Acta Neurol Scand; 1976 Mar; 53(3):189-200. PubMed ID: 773080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmaceutical review: salbutamol - madopar - isocal.
    Martin S
    Lamp; 1978 Mar; 35(3):34-9. PubMed ID: 418280
    [No Abstract]   [Full Text] [Related]  

  • 15. [Study of the M-H response, of the silent period and of post-tetanic potentiation in subjects with Parkinson's disease during treatment with L-dopa or Madopar].
    Ferro Milone F; Lorizio A; Nordera G
    Riv Neurol; 1975; 45(2):236-46. PubMed ID: 1179114
    [No Abstract]   [Full Text] [Related]  

  • 16. Levodopa/benserazide ('Madopar') combination therapy in elderly patients with parkinsonism.
    Williams BO; Carlyle D
    Curr Med Res Opin; 1979; 6(1):1-7. PubMed ID: 378553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
    Chouza C; Romero S; Gomensoro JB
    Acta Neurol Latinoam; 1974; 20(1-4):116-38. PubMed ID: 4619960
    [No Abstract]   [Full Text] [Related]  

  • 18. [Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
    Rondot P; Ziegler M; Aymard N; Holzer J
    Rev Neurol (Paris); 1987; 143(11):746-52. PubMed ID: 3324265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and side-effects of long term L-dopa therapy in Parkinsonian syndromes (evaluated by CT scan as well) (author's transl)].
    Quattrini A; Paggi A; Forastieri L; Del Pesce M; Di Bella P
    Riv Patol Nerv Ment; 1979 Jun; 99(5):289-97. PubMed ID: 388600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.
    Caraceni TA; Celano I; Parati E; Girotti F
    J Neurol Neurosurg Psychiatry; 1977 Dec; 40(12):1142-6. PubMed ID: 591982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.